Several Studies on Track for Ovarian and Breast Cancer Vaccine TPIV 200

Several Studies on Track for Ovarian and Breast Cancer Vaccine TPIV 200
The Phase 2 trial evaluating the combination of the TPIV 200 cancer vaccine with the immune checkpoint inhibitor Imfinzi (durvalumab) in ovarian cancer patients who progressed after receiving platinum-based chemotherapy has enrolled more than half of study participants, TPIV 200 developer TapImmune announced. The company also provided updates on the Phase 2 trial evaluating TPIV 200,

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *